Side-by-side · Research reference
CartalaxvsPinealon
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED10/32 cited
BHuman-MechanisticAUTO-DRAFTED12/36 cited
Cartalax
Bioregulator Peptide · Khavinson School
SQ · Protocol Unspecified
Pinealon
Pineal-derived · Neuroprotective
SQ or IM · Daily for 10 days · 1-2×/year
01Mechanism of Action
Parameter
Cartalax
Pinealon
Primary target
Mesenchymal stem cells (MSCs) undergoing chondrogenic differentiationLinkova 2023
Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014
Pathway
Modulation of WNT, ERK-p38, and Smad 1/5/8 signaling pathwaysLinkova 2023
Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014
Downstream effect
Upregulation of chondrogenic genes (COL2, SOX9, ACAN); increased bone mineral density; osteoprotective effects in ovariectomy-induced osteoporosisLinkova 2023Povorozniuk 2007
Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014
Feedback intact?
—
—
Origin
Derived from cartilaginous tissue extracts (Khavinson bioregulator methodology)Povorozniuk 2007
Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014
Antibody development
—
—
02Dosage Protocols
Parameter
Cartalax
Pinealon
Animal model dose
Unspecified (cartilaginous tissue extract protocol)
Rat study; extract preparation details not indexed in available abstracts.
—
Human dosing
Not established in PubMed-indexed literature
Russian-tradition protocols exist but lack peer-reviewed Western validation.
—
Frequency
—
Once daily during cycle
Lower / starter dose
—
2.5 mg / day
Duration
—
10-day cycles, 1–2× per year
Reconstitution
—
Bacteriostatic water
Timing
—
No specific time
Half-life
—
Hours
03Metabolic / Fat Loss Evidence
Parameter
Cartalax
Pinealon
Fat loss evidence
None — primary target is cartilage and bone tissue, not adipose
—
04Side Effects & Safety
Parameter
Cartalax
Pinealon
Documented adverse effects
None reported in indexed animal studies
—
Human safety data
Not available in PubMed-indexed literature
—
Injection site reaction
—
Mild irritation
Long-term safety
—
Limited Western data
Pregnancy / OB
—
Avoid
Absolute Contraindications
Cartalax
- ·Unknown due to lack of human clinical trial data
Pinealon
- ·Pregnancy / breastfeeding
Relative Contraindications
Cartalax
- ·Active malignancy (theoretical; peptide bioregulators may influence cell proliferation pathways)
Pinealon
- ·Active malignancy (theoretical via gene expression modulation)
05Administration Protocol
Parameter
Cartalax
Pinealon
1. Route
Subcutaneous injection typical for Khavinson bioregulators; specific protocols not detailed in indexed literature.
Add 1–2 mL bacteriostatic water to 10 mg vial.
2. Frequency
Russian-tradition protocols often employ 10-day cycles; precise frequency unspecified in available abstracts.
SQ — abdomen preferred.
3. Storage
Lyophilised peptide bioregulators typically stored at 2–8 °C, light-protected. Reconstitution details not indexed.
Daily during cycle, any time.
4. Storage
—
Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.
5. Needle
—
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Cartalax
— no documented stacks
Pinealon
+ Epitalon
ModeratePinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.
- Pinealon
- 5–10 mg SQ · daily × 10 days
- Epitalon
- 5–10 mg SQ · daily × 10 days (overlap or alternate)
- Primary benefit
- Neuroprotection + telomere preservation